Product How it works Pricing Blog FAQ About Contact
Español English
EspañolEnglish
Log inCreate free account
Precision Biosciences

Precision Biosciences (NASDAQ: DTIL) insider transactions

In the twelve months to 10 November 2026, executives and directors of Precision Biosciences reported 8 open-market sales of 107,624 shares ($431,271) and 6 open-market purchases of 11,825 shares ($63,215), by 7 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in Precision Biosciences shares reported on Form 4
DateInsiderRoleTransactionSharesPriceHeld afterFiling
28 September 2026Frankel StanleyDirectorOpen-market purchase+1,000$6.0041,478Form 4
25 September 2026Germano Geno JDirectorOpen-market purchase+2,609$6.2847,492Form 4
25 September 2026Brown MelindaDirectorOpen-market purchase+1,135$6.2745,481Form 4
20 May 2026Germano Geno JDirectorOption exercise+21,000—44,883Form 4
20 May 2026Pire Shari LisaDirectorOption exercise+21,000—35,028Form 4
20 May 2026Brown MelindaDirectorOption exercise+21,000—44,346Form 4
20 May 2026Frankel StanleyDirectorOption exercise+21,000—40,478Form 4
20 May 2026Buehler KevinDirectorOption exercise+21,000—49,137Form 4
18 February 2026Smith J. JeffersonChief Research OfficerOpen-market sale, 10b5-1 plan−4,925$3.84121,926Form 4
18 February 2026Scimeca DarioGeneral Counsel and SecretaryOpen-market sale, 10b5-1 plan−4,925$3.8456,457Form 4
18 February 2026Kelly John AlexanderChief Financial OfficerOpen-market sale, 10b5-1 plan−8,149$3.84125,883Form 4
18 February 2026Amoroso MichaelPresident and CEOOpen-market sale, 10b5-1 plan−20,559$3.84243,392Form 4
17 February 2026Smith J. JeffersonChief Research OfficerOption exercise, 10b5-1 plan+16,667—126,851Form 4
17 February 2026Scimeca DarioGeneral Counsel and SecretaryOption exercise, 10b5-1 plan+16,667—61,382Form 4
17 February 2026Kelly John AlexanderChief Financial OfficerOption exercise, 10b5-1 plan+27,584—134,032Form 4
17 February 2026Amoroso MichaelPresident and CEOOption exercise, 10b5-1 plan+67,797—263,951Form 4
22 January 2026Amoroso MichaelPresident and CEOOpen-market sale, 10b5-1 plan−34,799$4.17196,154Form 4
21 January 2026Smith J. JeffersonChief Research OfficerOption exercise, 10b5-1 plan+16,219—120,384Form 4
21 January 2026Smith J. JeffersonChief Research OfficerOpen-market sale, 10b5-1 plan−10,200$4.03110,184Form 4
21 January 2026Kelly John AlexanderChief Financial OfficerOpen-market sale, 10b5-1 plan−15,213$4.03106,448Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Precision Biosciences page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.